PT - JOURNAL ARTICLE AU - Stacey, Hannah AU - Carlock, Michael A. AU - Allen, James D. AU - Hanley, Hannah B. AU - Crotty, Shane AU - Ross, Ted M. AU - Einav, Tal TI - Leveraging Pre-Vaccination Antibody Titers across Multiple Influenza H3N2 Variants to Forecast the Post-Vaccination Response AID - 10.1101/2024.08.01.24311325 DP - 2024 Jan 01 TA - medRxiv PG - 2024.08.01.24311325 4099 - http://medrxiv.org/content/early/2024/08/03/2024.08.01.24311325.short 4100 - http://medrxiv.org/content/early/2024/08/03/2024.08.01.24311325.full AB - Despite decades of research on the influenza virus, we still lack a predictive understanding of how vaccination reshapes each person’s antibody response, which impedes efforts to design better vaccines. Here, we combined fifteen prior H3N2 influenza vaccine studies from 1997-2021, collectively containing 20,000 data points, and demonstrate that a person’s pre-vaccination antibody titers predicts their post-vaccination response. In addition to hemagglutination inhibition (HAI) titers against the vaccine strain, the most predictive pre-vaccination feature is the HAI against historical influenza variants, with smaller predictive power derived from age, sex, BMI, vaccine dose, the date of vaccination, or geographic location. The resulting model predicted future responses even when the vaccine composition changed or a different inactivated vaccine formulation was used. A pre-vaccination feature ‒ the time between peak HAI across recent variants ‒ distinguished large versus small post-vaccination responses with 73% accuracy. As a further test, four vaccine studies were conducted in 2022-2023 spanning two geographic locations and three influenza vaccine types. These datasets formed a blinded prediction challenge, where the computational team only received the pre-vaccination data yet predicted the post-vaccination responses with 2.2-fold error, comparable to the 2-fold intrinsic error of the experimental assay. This approach paves the way to better utilize current influenza vaccines, especially for individuals who exhibit the weakest responses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the University of California San Diego PREPARE Institute, the National Center for Advancing Translational Sciences of the NIH (CTRU, Award #UL1TR002378), the Collaborative Influenza Vaccine Innovations Centers (CIVICs) of NIAID (Contract #75N93019C00052), the University of Georgia, the Cleveland Clinic, and by the Georgia Research Alliance (TMR, Georgia Eminent Scholar GRA-001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of the University of Georgia gave ethical approval for this work. The IRB of WCG Clinical gave ethical approval for this work. The IRB of the La Jolla Institute for Immunology gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes